Home › Pulmonary Embolism › NCT06433011
The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism
The RAPID - PE Study: RESCUE Advanced Protocol Without ICU Stay and no Lytic Drip - for the Treatment of Pulmonary Embolism
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria 1. Willing and able to provide informed consent; 2. PE symptom duration ≤ 15 days; 3. Filling defect in at least one major lobar pulmonary artery as determined by CTA; 4. Patient is diagnosed with intermediate risk PE; 5. RV/LV diameter ratio ≥ 0.9 by CTA, as determined by investigative site; 6. Willing and able to comply with all study procedures and 7-day and 30-day telephone follow-up visit. Exclusion Criteria: 1. Previous history of stroke with residual hemiplegia; 2. Major surgery ≤ 10 days prior to inclusion in the study; 3. Platelet count \< 100,000/μL; 4. Pulmonary thrombectomy within the previous 4 days; 5. Uncontrolled hypertension defined as systolic blood pressure \>180 mm Hg and/or diastolic blood pressure \>110 mm Hg at the time of the procedure; 6. Administration of thrombolytic agents within the previous 4 days; 7. Absolute contraindication to anticoagulation; 8. Clinician deems high-risk for catastrophic bleeding; 9. Pregnancy; 10. Any vasopressor or inotropic support; 11. Cardiac arrest (including pulseless electrical activity (PEA) and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and/or referring institution; 12. Planning to administer r-tPA by infusion after the r-tPA is administered by pulse sprays; 13. Currently participating in another study; 14. In the opinion of the investigator, the subject is not a suitable candidate for the study.
About the study
To demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment of intermediate risk pulmonary embolism (PE).
What is being tested
- The Bashir™ Endovascular Catheter (device)
- r-tPA (drug)
Sponsor: Thrombolex, Inc. · Participants: 500 · Started: Oct 17, 2024
Contact the study team
- Chris Schultz, BS · Phone: 971-506-7552
- Craig Dull, MS · Phone: 314-315-6264
Official record on ClinicalTrials.gov — NCT06433011
Locations in the U.S.
| Arizona | Honor Health, Scottsdale Carondelet St. Joseph's Hospital, Tuscon |
| Florida | Radiology and Imaging Specialists, Lakeland |
| Georgia | Emory University, Atlanta |
| Illinois | Rush University Medical Center, Chicago |
| Indiana | Profound Research, Hobart Community Health, Indianapolis |
| Massachusetts | Beth Israel Deaconess Medical Center, Boston Boston Medical Center, Boston Lahey Hospital & Medical Center, Burlington |
| Mississippi | North Mississippi Medical Center, Tupelo |
| New Hampshire | Dartmouth Hitchcock, Lebanon |
| New Jersey | Cooper Health, Camden |
| New York | St. Joseph's, Liverpool Northwell Health, Manhasset Mount Sinai, New York |
| Ohio | TriHealth, Cincinnati Miami Valley/Wright State University/Premier Health, Dayton Jobst Vascular Institute - ProMedica Hospital, Toledo |
| Pennsylvania | Temple University, Philadelphia |
| Tennessee | Vanderbilt University Medical Center, Nashville |
| Virginia | Sentara, Norfolk |
| West Virginia | Charleston Area Medical Center, Charleston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.